Effects omega-3 fatty acid supplementation in the treatment of diabetes

Effects of omega-3 fatty acid supplementation on metabolic profiles, hs-CRP and biomarkers of oxidative stress in diabetic nephropaty patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201502255623N36

Enrollment

Registered

2015-03-10

Start date

2015-03-11

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy. Insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention group: Omega-3 fatty acid pearl, 1000 mg, daily, for 12 weeks orally. Intervention 2: Control group: Placebo pearl, daily, for 12 weeks orally.

Eligibility

Sex/Gender

All

Age

45 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patients with diabetic nephropathy aged 45 to 85 years. Proteinuria level>0.3 g/24 h, with or without elevation of serum creatinine levels

Exclusion criteria

Exclusion criteria: The intake of omega-3 fatty acid supplements within 3 months Patients with uncontrolled diabetes The current use of warfarin Malignancy and/or liver cirrhosis.

Design outcomes

Primary

Measure	Time frame
Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Calculation using HOMA formula.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: ELISA kit.	—

Secondary

Measure	Time frame
High-sensitivity C-reactive protein. Timepoint: Baseline and End-of-trial. Method of measurement: ELISA test.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Fasting blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;LDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Blood Urea Nitrogen. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Serum Creatinine. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.	—

Measure

Time frame

High-sensitivity C-reactive protein. Timepoint: Baseline and End-of-trial. Method of measurement: ELISA test.;Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Triglycerides. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;HDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Fasting blood sugar. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;LDL. Timepoint: Baseline and End-of-trial. Method of measurement: Enzymatic kit.;Blood Urea Nitrogen. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Serum Creatinine. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_r@yahoo.com+98 31 5562 0608

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026